RLYB vs FSEA Comparison

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

First Seacoast Bancorp Inc is the savings and loan holding company. The banks business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one- to four-family residential real estate loans, commercial real estate and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. It operates in single segment of Banking Services.